Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 9:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 330 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Heart transplant patients Clear all
Completed No phase listed Observational

Noninvasive Methods to Monitor Graft Survival in Heart Transplant Patients

NCT00466804
View directory record Official record
Conditions
Heart Transplant
Interventions
Heart transplant
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
10 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
12
States / cities
San Francisco, California • Chicago, Illinois • Maywood, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 14, 2026, 9:56 AM EDT
Active, not recruiting Phase 2 Interventional Results available

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

NCT04214249
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, Secondary Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Hematopoietic Cell Transplantation, Idarubicin Hydrochloride, Multigated Acquisition Scan, Pembrolizumab, Punch Biopsy
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • Orange, California • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 14, 2026, 9:56 AM EDT
Terminated Phase 3 Interventional

Atopic Dermatitis-Like Skin Disease in Pediatric Heart Transplant Patients

NCT00176956
View directory record Official record
Conditions
Dermatitis
Interventions
Skin Biopsy
Procedure
Lead sponsor
Hordinsky, Maria K., MD
Individual
Eligibility
Up to 16 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Oct 14, 2026, 9:56 AM EDT
Enrolling by invitation Phase 2 Interventional

The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients

NCT03292861
View directory record Official record
Conditions
Heart Transplantation
Interventions
Thymoglobulin, Mycophenolate Mofetil, Tacrolimus, Sirolimus, Corticosteroids
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 14, 2026, 9:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Don't Throw Your Heart Away: Patient Study 4

NCT04809051
View directory record Official record
Conditions
Cardiac Transplant Disorder
Interventions
Stratified Transplant Survival Metric, SRTR Information Format
Other
Lead sponsor
Carnegie Mellon University
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Oct 14, 2026, 9:56 AM EDT
Terminated No phase listed Observational

The Epidemiology of Bleeding and Clotting in Patients Undergoing Heart Transplantation, Coronary Artery Bypass Graft Surgery,or Implantation of Left Ventricular Assist Devices

NCT01481012
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
13
States / cities
Birmingham, Alabama • San Diego, California • Oak Lawn, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2011 · Synced Oct 14, 2026, 9:56 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors (HCV)

NCT03146741
View directory record Official record
Conditions
Heart Failure
Interventions
Zepatier
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Oct 14, 2026, 9:56 AM EDT
Terminated Not applicable Interventional

Del Nido Cardioplegia Randomized Trial

NCT02442050
View directory record Official record
Conditions
Cardiac Perfusion
Interventions
del Nido solution, Blood-based cardioplegia
Other
Lead sponsor
Inova Health Care Services
Other
Eligibility
19 Years to 79 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Oct 14, 2026, 9:56 AM EDT
Completed Not applicable Interventional

Peri-Operative Morbidity and Quality of Life After Coronary Artery Bypass Graft (CABG)

NCT00248885
View directory record Official record
Conditions
Coronary Artery Bypass Graft Surgery
Interventions
Regulating Mean Arterial Pressure during cardiopulmonary bypass
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 1994
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2008 · Synced Oct 14, 2026, 9:56 AM EDT
Recruiting Not applicable Interventional

Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts

NCT02323581
View directory record Official record
Conditions
Aortic Aneurysm, Thoracoabdominal, Aortic Aneurysm, Thoracic, Aortic Dissection, Thoracoabdominal
Interventions
Endovascular treatment of Thoracoabdominal Aortic Aneurysm, Endovascular treatment of Aortic Arch Aneurysms
Device
Lead sponsor
Darren Schneider, M.D.
Other
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2033
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 14, 2026, 9:56 AM EDT
Completed Phase 3 Interventional Results available

Coronary Artery Vasculopathy in Pediatric Heart Transplant Patients

NCT03231371
View directory record Official record
Conditions
Orthotopic Heart Transplant
Interventions
Adenosine
Drug
Lead sponsor
Bryan Goldstein
Other
Eligibility
1 Year to 25 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Oct 14, 2026, 9:56 AM EDT
Completed Phase 3 Interventional Results available

The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation

NCT02013037
View directory record Official record
Conditions
Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant, Left Ventricular Dysfunction, Cardiac Allograft Vasculopathy, Heart Graft Dysfunction
Interventions
Eculizumab
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 14, 2026, 9:56 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Feasibility Study of BMAC Enhanced CABG

NCT01074099
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
BMAC, CABG only
Biological · Procedure
Lead sponsor
Harvest Technologies
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Houston, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Oct 14, 2026, 9:56 AM EDT
Recruiting Phase 2Phase 3 Interventional

Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant

NCT07079735
View directory record Official record
Conditions
CMV Viremia, Heart Transplant Infection, Heart Transplant Failure and Rejection
Interventions
Letermovir, Valganciclovir
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 99 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 14, 2026, 9:56 AM EDT
Terminated Phase 1 Interventional Results available

High Dose Vitamin C in Cardiac Surgery Patients

NCT02762331
View directory record Official record
Conditions
Disorder of Vitamin C, Atrial Fibrillation, Complications Due to Coronary Artery Bypass Graft, Heart Valve Disease
Interventions
Ascorbic Acid, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Oct 14, 2026, 9:56 AM EDT
Terminated Not applicable Interventional

Clinical Trial to Evaluate the the ReliantHeart HeartAssist 5® VAD System in Patients Awaiting Heart Transplantation

NCT02205411
View directory record Official record
Conditions
Heart Failure, Cardiac Failure, Congestive Heart Failure, Heart Failure, Left-sided
Interventions
HeartAssist 5® VAD System, Control VAD
Device
Lead sponsor
ReliantHeart Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
14
States / cities
San Francisco, California • Stanford, California • Coral Gables, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 14, 2026, 9:56 AM EDT
Recruiting No phase listed Observational

Assessment of Microvascular Circulation in the Pediatric Cardiac Surgery Patient

NCT07184476
View directory record Official record
Conditions
Tetrology of Fallot
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Day to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 14, 2026, 9:56 AM EDT
Completed Phase 3 Interventional

Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)

NCT00088179
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
pexelizumab in conjunction with CABG
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
182
States / cities
Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 129 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 14, 2026, 9:56 AM EDT
Completed No phase listed Observational

MRI to Predict Rejection and Failure in Transplant and Cardiomyopathy Patients

NCT03822442
View directory record Official record
Conditions
Heart Failure, Cardiac Imaging Techniques, Congenital Heart Defects
Interventions
Not listed
Lead sponsor
Children's National Research Institute
Other
Eligibility
6 Months and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 14, 2026, 9:56 AM EDT
Completed Phase 3 Interventional Results available

Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant

NCT02118896
View directory record Official record
Conditions
Heart Transplantation, Liver Transplantation, Kidney Transplantation
Interventions
FK506E
Drug
Lead sponsor
Astellas Pharma Europe Ltd.
Industry
Eligibility
18 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 14, 2026, 9:56 AM EDT
Terminated Phase 4 Interventional

Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients

NCT00121784
View directory record Official record
Conditions
Heart Transplantation
Interventions
mycophenolate mofetil [CellCept]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
11
States / cities
Chicago, Illinois • Maywood, Illinois • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 14, 2026, 9:56 AM EDT
Not listed No phase listed Observational

The Natural History of Danon Disease

NCT03766386
View directory record Official record
Conditions
Danon Disease
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
0 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Oct 14, 2026, 9:56 AM EDT
Completed Phase 1 Interventional

Daratumumab-SC for Highly Sensitized Patients Awaiting Heart Transplantation

NCT04610320
View directory record Official record
Conditions
Allosensitization, Heart Transplant Failure and Rejection
Interventions
Daratumumab-SC
Drug
Lead sponsor
Ronald Witteles
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Oct 14, 2026, 9:56 AM EDT
Completed No phase listed Observational

Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation

NCT02598752
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Hematological Malignancy, Leukemia, Lymphoma, Myeloma
Interventions
Symptom-limited cardiopulmonary exercise test (CPET), Resting assessment of cardiac function by echocardiography, Post-exercise assessment of cardiac function by echocardiography, Pulmonary function, Patient-reported outcomes questionnaire
Other · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 14, 2026, 9:56 AM EDT